FORMYCON AG |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 43.75 EUR | +1.27% |
|
+4.69% | -22.78% |
| Apr. 25 | Formycon AG Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Mar. 18 | Formycon, Fresenius Kabi Sign Settlement Deal with Johnson & Johnson for Ustekinumab Biosimilar | MT |
Evolution of the average Target Price on Formycon AG
Price target over the last 5 years
History of analyst recommendation changes
5db086cdd7790f0aeef053f8ad02a.fFNJstUgJgSds_mmqU7IsmUN7NjhKOQUvdK0_t8UxPs.Fisl-IdQUDzJyY3w_ni75Dp8grOxfoBw6v_Bt5l8vY4rIQTEgxhRbfjloA~23c3b9dd6968c2a6339d1a2f8d24bb1a
Analysts' Consensus
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
43.2
EUR
Average target price
91.8
EUR
Spread / Average Target
+112.50%
High Price Target
101
EUR
Spread / Highest target
+133.80%
Low Price Target
81
EUR
Spread / Lowest Target
+87.50%
Consensus detail
Consensus revision (last 18 months)
Trading Rating
Investor Rating
ESG Refinitiv
EPS Revisions
Annual profits - Rate of surprise
- Stock Market
- Equities
- FYB Stock
- Consensus Formycon AG